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Extravasation Injuries for the Plastic Surgeon
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Benjamin Mitchell, BS*
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Albert K. Oh, MD‡
Jerry W. Chao, MD‡¶

Intravenous therapy is a common practice among many specialties. Intravenous
therapy extravasation is a potential complication to such therapy. Hospitals without
a dedicated wound care team trained in these interventions will often default to
plastic surgical consultation, making an understanding of available interventions
essential to the initial evaluation and management of these injuries. The goal of
this article was to provide plastic surgeons and health care providers with a general
overview of the acute management of intravenous infiltration and extravasation
injuries. Though the decision for surgical versus nonsurgical management is often a clear one for plastic surgeons, local interventions, and therapies are often
indicated and under-utilized in the immediate postinfiltration period. Thorough
knowledge of these interventions should be a basic requirement in the armamentarium of plastic surgery consultants. (Plast Reconstr Surg Glob Open 2018;6:e1743;
doi: 10.1097/GOX.0000000000001743; Published online 19 April 2018.)

INTRODUCTION

Originating in the mid 1600s in Germany, intravenous infusion has progressed considerably from the once
used feather quills to greater than a million chemotherapeutic infusions per day.1,2 Intravenous therapy (IVT) is
prevalent in every medical specialty, with a diversity of applications including anesthesia, rehydration, transfusion,
drug delivery, parenteral nutrition, central venous pressure monitoring, dialysis, contrast imaging, and countless
other important applications.3 With such substantial use,
infiltration and extravasation injuries to the soft tissue are
commonplace, occurring in up to 6% of patients.4
Iatrogenic complications of IVT include infection,
phlebitis, infiltration, extravasation, soft-tissue necrosis,
and compartment syndrome.3,5 Severity often correlates
with the characteristics of the injected solution. Though
the terms are often used interchangeably, strictly speakFrom the *Georgetown University School of Medicine, Washington,
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ing, infiltration refers to leakage of nonvesicant (nonirritating) solution into the extravascular space,6,7 while
extravasation involves a vesicant (irritating) solution.6
Various agents induce soft-tissue injury through distinct mechanisms. Vasoactive agents induce vasoconstriction causing ischemia and subsequent necrosis.7
Electrolyte-rich solutions alter the electrical potential
and subsequent tone in pre- and postcapillary sphincters
leading to ischemia.7 Hyperosmolar solutions cause a
fluid shift from vascular and cellular compartments into
the surrounding tissues leading to elevated compartment
pressures and potentially compartment syndrome.7,8
Finally, cytotoxic solutions are directly toxic to the surrounding tissues.
Plastic surgeons and trainees are often on the forefront of management of these injuries.5 Treatment in the
inpatient setting is not an emphasized part of the standard
plastic surgery curriculum, and consequently, many trainees remain unaware of interventions outside the realm
of antibiotic ointments, debridement, and soft-tissue reconstruction. This is despite compelling data that shows
a benefit with certain early interventions. Adding to the
confusion with the standard of care is the variation and
inconsistency among many hospital-specific guidelines,9,10
as many treatments have only an anecdotal basis. As an
essential component of the wound management team in
many settings, plastic surgeons should be knowledgeable
and involved in the development of guidelines to minimize iatrogenic morbidity. The objective of this article was
to provide an evidence-based review of extravasation injuries relevant to plastic surgeons and trainees.
Disclosure: The authors have no financial interest to
declare in relation to the content of this article. The Article
Processing Charge was paid for by the authors.
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Recognition and Classification

Immediate symptoms of IVT extravasation may include blanching of the skin, discomfort, edema, changes
in IV flow, and fluid leakage (Table 1).3 Early recognition
is important. There are multiple classifications of extravasations. The United States Department of Health and
Human Services, National Cancer institute, and National
Institute of Health published the Common Terminology
Criteria for Adverse Events (Version 4.0 of May 2009),
which includes a devised 5-point grading system for extravasation (Table 2).11,12
The peripheral intravenous infiltration and extravasation
scale is a more recently developed scale, dependent upon
the proportion of appendage affected rather than exclusively
the length of the infiltrated area. This ratio is determined
by measuring the maximum dimension of edema (width or
length) and dividing by the length of the appendage (axilla to longest finger or groin to longest toe).13 There are 3
grades (Table 3): mild (< 30% affected), moderate (30–60%
affected), and severe (> 60% affected), with suggested interventions based on the severity of limb involvement.
Nonpharmacologic Management

Following identification, IVT should immediately be
discontinued while keeping the catheter in place, allowing for potential aspiration of the infiltrated agent with 3–
Table 1. Symptoms of IV Extravasation2,3
1. Blanched skin that may feel cool to the touch
2. Pressure, swelling, a patient saying skin feels “tight”
3. Discomfort, pain, and tenderness
4. Insertion site edema
5. Alterations to the IV flow
6. Leakage of infused fluid at the insertion site

Table 2. Common Terminology Criteria for Adverse Events:
Grading System for IV Extravasation Injuries12
1. Intact skin
2. Blanched skin, erythema
3. Necrosis or ulceration causing severe tissue damage; indicates
surgical intervention
4. Life-threatening consequences; indicates immediate intervention
5. Death

Table 3. The Peripheral Intravenous Infiltration and
Extravasation Scale used in Pediatric Infiltration and
Extravasation Injuries (Adapted from Scale Originally by
Children’s Medical Center of Dallas)13
1. Mild
a. Swelling < 30%
b. No blistering
c. Normal, blanched skin
2. Moderate
a. Swelling 30–60%
b. Diminished pulse distal to IVT infiltration
c. Close monitoring and follow-up
3. Severe
a. 60%
b. Fasciotomy or debridement
c. Full-thickness skin loss
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5 mL of blood using a 10 mL syringe.14,15 A reversal agent,
if available, may also be administered via the catheter, followed by removal. Maneuvers to reduce edema, such as
limb elevation, should be instituted.
Thermal compresses are commonly utilized in the
acute period, though their efficacy outside of increasing
patient comfort remains anecdotal with no controlled
studies.16,17 They are typically administered for 20 minutes 4 times per day for 1–2 days.15 In theory, cold compresses elicit local vasoconstriction, which can reduce
pain, local inflammation, and the further spread of the
infused agent—useful for infiltration by hyperosmolar
solutions such as Total Parenteral Nutrition (TPN).
Cold compresses are contraindicated for cases of infiltration by vasopressors, vinca alkaloids, and epipodophyllotoxins (etoposide) due to evidence of subsequent
further deterioration.9,11,15 In contrast, warm compresses
cause local vasodilation and are preferred for vasopressors, vinca alkaloids, phenytoin, and contrast media.14
The local vasodilation is thought to increase blood flow,
thereby augmenting drug disposal. Regardless of the
lacking evidence, compresses are soothing to the patient
and are recommended for that reason.
Support for manual extraction methods is sparse
and anecdotal. Some reported interventions, such as the
squeeze maneuver or the multiple puncture procedure, involve using an 18-gauge needle to make 5–8 fenestrations
at the peri-insertion area and subsequent compression
proximal to the extravasation to liberate the infiltrated
vesicant in adult infiltrations.18,19 Early subcutaneous washout has been documented to be quite successful especially
within 6 hours of the extravasation injury. In this method,
isotonic saline is infiltrated through a liposuction cannula.
The fluid is then removed by careful suction through the
cannula. This procedure is repeated until 300–500 mL has
been removed in total.20 The success of washout may be
due to a prompt reduction of the infiltrated agent’s concentration.
In cases of soft-tissue ischemia or necrosis, the area of
injury should be protected with a nonadherent dressing,
which provides a protective barrier. Topical antimicrobials
or a wound gel are also routinely used to promote a moist
wound environment. Reassessments are paramount by a
plastic surgery or wound team to be sure no further serious injury is noted.
Pharmacologic Management

The propensity for damage and the subsequent management of an infiltration insult is highly dependent upon
the physiochemical characteristics of the extravasated
agent.21 Those most commonly associated with extravasations will be described below.
Vasopressors

Extravasation by vasopressors (vasopressin, norepinephrine, epinephrine, dopamine, and dobutamine) causes
local vasoconstriction, resulting in tissue ischemia and necrosis6 (Figs. 1, 2). Though ordinarily administered via large
central veins,22 peripheral infusion of vasopressors is sometimes performed to hasten the placement of IV access.22
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sin exerts its vasoactive properties via the V1 receptor, and
there are currently no reports of successful intervention
with a direct reversal agent. Phentolamine, terbutaline, or
topical nitroglycerin may provide some protective effect
in vasopressin infiltrations via their inherent vasodilatory
effects.14
Phentolamine is a reversible alpha-adrenergic receptor
antagonist.14 For neonates, the provider should perform a
1:10 dilution of the commercial 5 mg/mL phentolamine
to a concentration of 0.5 mg/mL, followed by 5 injections
of 0.2 mL of phentolamine into the area of extravasation.19
For infants, children, and adults, 5 mg of phentolamine
reconstituted with 5 mL of normal saline (1 mg/mL) or
a 1:5 dilution should be performed of the commercially
available 5 mg/mL phentolamine to attain a final concentration of 1 mg/mL phentolamine. The solution should
be injected in 0.5–1 mL aliquots 5 times around the injection site using a 25-gauge or 27-gauge needle.25 Phentolamine’s effects are time dependent with no beneficial
outcome observed after 13 hours of the injury14 (Fig. 4).
Nitroglycerin can be given to augment phentolamine-mediated vasodilation. Topical application of 2.5 cm of 2%
nitroglycerin paste with reapplication every 8 hours has
been shown to initiate reperfusion.14
Osmotically Active Agents

Fig. 1. A 11-year-old female with dopamine extravasation 5 days
post infusion. Treated with warm compress and phentolamine.

Fig. 2. A 32-week premature infant with a dopamine extravasation 2
months post infusion.

Vasoconstriction occurs via an α-1–mediated response,
with norepinephrine being the most commonly reported
cause of vasopressor-mediated infiltration.14 Dopamine
and epinephrine (β-1, β-2, and α-1 agonist) also function on α-1 receptors. Phentolamine may serve as a local
therapy/reversal agent in these cases23,24 (Figs. 2, 3). In a
study of 734 patients receiving peripheral intravenous vasopressors, there was a 2% incidence of infiltration.25 In
all cases, local phentolamine was injected in addition to
application of a nitroglycerin paste, and no patients experienced irreversible tissue necrosis. In contrast, vasopres-

Infiltration of hypertonic solutions [TPN, peripheral
parenteral nutrition (PPN), dextrose > 10%, sodium bicarbonate, potassium, and calcium 26) causes an imbalance in the equilibrium between the intracellular and
extracellular compartments, causing fluid shifts, cellular
dysfunction, and cell damage/death. Accumulation of fluid further compromises the tissue compartment through
hypoperfusion and subsequent tissue necrosis14 (Fig. 5). A
retrospective study on 352 patients receiving PPN found
a 40% incidence of phlebitis or infiltration. Those receiving PPN with osmolarity greater than 1,000 mOsm/L had
a 17% incidence versus 7% incidence in patients receiving PPN with an osmolarity less than 1,000 mOsm/L.27 In
these cases, the patient must be evaluated and monitored
for compartment syndrome, with a low threshold to obtain a compartment pressure or perform fasciotomies if
clinically suspicious (positive if greater than 30 mm Hg).28
Hyaluronidase is often utilized for treating hypertonic
extravasations, though not Food and Drug Administration
(FDA) approved for this indication.14 Although there are
conflicting data regarding its efficacy, most case studies
report that hyaluronidase augments dispersion of the extravasated agent.29 However, no randomized clinical studies
have been performed to date.30 Hyaluronidase functions
via depolymerization of glycosaminoglycans such as chondroitin sulfate and hyaluronic acid, which is thought to
increase tissue permeability and subsequently aid in dispersion of the infiltrated agent (technique described below
under cytotoxic drugs section). Local injection of hyaluronidase and saline washout is the current principle modality
to treat severe TPN-associated extravasations; however, this
is based on limited studies14 (Fig. 5). Hyaluronidase was
shown to be successful in the treatment of 2 cases of TPN
extravasations with improvement in 6–12 hours.31
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Fig. 3. A, A 5-day old full-term neonate with an R lower leg IV extravasation; dopamine and PPN were
infusing. Treated initially with phentolamine and elevation. B, 30-day Status post healing by secondary
intention, with residual cosmetic skin changes.

Fig. 4. A, Severe epinephrine extravasation injury to the neck. Therapies including subcutaneous phentolamine and topical nitroglycerin paste were utilized after identification. Nevertheless, substantial irreversible tissue ischemia occurred, possibly due to a delay in identification. B, Debridement of necrotic
skin and subcutaneous tissue was performed.

Contrast Media

Fig. 5. A 3-month-old infant with a TPN infiltrate 1 week post infusion. Treated with hyaluronidase and elevation.
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Contrast media extravasation carries an incidence of
0.1–0.9%32,33 and is usually minor and self-resolving; however, it can escalate to more serious complications.32,34
Extravasated contrast media is toxic to the surrounding
tissues and is associated with an inflammatory response
that peaks between 24 and 48 hours.32 The mechanism of
toxicity is similar to that of osmotically active agents, as its
hypertonicity results in fluid shifts.32
There is no evidence-based consensus on management; however, most commonly, the limb is elevated
and treated with a warm compress.33 The efficacy of this
maneuver is not proven.16,32 The attempted aspiration of
contrast media, liposuction, or injection of local therapies
such as hyaluronidase or corticosteroids has no evidential
support for the treatment of a contrast media extravasation.32 As in all extravasation injuries, monitoring of the
patient for progression of symptoms, such as progressive
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neurologic or vascular complications, is appropriate and
necessary.33

Table 4. Classes of Cytotoxic Drugs2,9

Cytotoxic Drugs

Vesicants

Cytotoxic drugs are grouped into 5 categories: irritants, inflammitants, exfoliants, vesicants, and neutrals (Table 4),11 with each causing characteristic clinical
pictures of soft-tissue damage. Below, we will review the
described pharmacologic interventions for these chemotherapeutic extravasations.
Hyaluronidase

Hyaluronidase degrades glycosaminoglycans and
hyaluronic acid, with subsequent increases in tissue
permeability and dispersion of extravasated agent.11,14 Hyaluronidase has been used for extravasation by etoposide,
taxanes (ie, paclitaxel, docetaxel, and cabazitaxel), and
vinca alkaloids.11 Although hyaluronidase is recognized as
therapeutic for extravasation, there is much inconsistency
with regard to proper technique and dosage. Additionally,
there is a dearth of controlled, nonanecdotal studies proving its efficacy.
Rat studies have shown hyaluronidase to be effective
at reducing the wound size and healing time in vinorelbine-induced extravasations.35 In 1994, hyaluronidase was
also effective at preventing necrosis in 7 patients with accidental vinca alkaloid extravasation.36 Despite the poor
evidence-based strength of recommendation, it is worth
noting that the manufacturers of vinblastine indicate the
use of hyaluronidase if extravasation occurs.37,38
Recent guidelines, especially for chemotherapeutic extravasations in adults, recommend a dosage of 150 units
of hyaluronidase.30 However, dosage varies among institutions. For Amphadase (Amphastar Pharmaceuticals,
Rancho Cucamonga, Calif.), Hydase (Akorn, Lake Forest, Ill.), and Hylenex (Baxter Healthcare Corporation,
Deerfield, Ill.), vials contain 150 units/mL, which do not
need further dilution.30 Vitrase (ISTA Pharmaceuticals,
Irvine, Calif.) contains 2 mL of 200 units hyaluronidase,
which should be further diluted in a 3:1 ratio of vitrase to
normal saline (0.75 mL of vitrase solution with 0.25 mL of
normal saline). Hyaluronidase (150 unit in 1 mL) should
be administered through five 0.2 mL subcutaneous injections into the extravasation site.
For pediatric patients, it has been shown that the administration of 15 units of hyaluronidase is effective to
resolve the extravasation.19 This dilution is achieved with
0.1 mL (150 unit/mL) hyaluronidase solution with 0.9 mL
of normal saline, yielding the desired 15 units/mL for injection. The administration should be done immediately,
with benefit seen when given within 3 hours of insult. In
pediatric patients or infants, a 27–30 gauge needle is used
to inject five 0.2 mL injections of hyaluronidase around
the infiltration site in a circular pattern.19,30,39
Dexrazoxane Hydrochloride

Dexrazoxane [Zinecard (Pfizer, New York City), Savene
and Totect (Clinigen Group Plc, Burton-on-Trent, United
Kingdom)] is an FDA-approved local therapy for anthracycline (daunorubicin, doxorubicin) extravasation,11 which

Class

Examples

Actinomycin D
Doxorubicin
Mitomycin C
Exfoliants
Cisplatin
Oxaliplatin
Paclitaxel
Irritants
Carboplatin
Etoposide
Topotecan
Inflammitants 5-fluorouracil
Methotrexate
Neutrals
Rituximab
Trastuzumab; eribulin

Clinical Picture
Inflammation, blistering of
skin, pain, tissue death,
and necrosis
Inflammation and blistering,
not usually associated with
tissue death
Local inflammation and
irritation
Moderate inflammation in
local tissues
Inert, no inflammation or
direct tissue damage

commonly results in severe tissue damage. Its mode of
action is not well understood.11,40 Two prospective clinical
trials, TT01 and TT02, were conducted to determine the
efficacy and tolerability of treatment with dexrazoxane
[Savene (Clinigen Group Plc, Burton-on-Trent, United
Kingdom)]. These studies, unlike other extravasation
studies, used fluorescence biopsies to objectify the diagnosis of extravasation.41 Fifty-four patients were confirmed to
have anthracycline extravasation. The 54 patients underwent dexrazoxane treatment: 1,000 mg/m2 within 6 hours
of insult, 1,000 mg/m2 24 hours after initial treatment,
and 500 mg/m2 48 hours after initial treatment.41 Of the
54 patients receiving treatment, only 1 patient required
a surgical intervention, an efficacy rate of 98%.41,42 In addition, over two-thirds the patients had no resultant delay
in chemotherapeutic treatment secondary to soft-tissue
wounds.41,42
Indication for dexrazoxane administration is extravasation of more than 5 mL of an anthracycline drug.9 It is
contraindicated in the following patient populations: less
than 18 years old, hepatic or renal insufficiency, recent
inoculation with a live vaccine, and patients receiving phenytoin.9,43 It may also be teratogenic and should be avoided during pregnancy.44
The treatment consists of a 3-day course of IV dexrazoxane.45 The first dose of 1,000 mg/m2 is ideally administered as soon as possible, followed by 1,000 mg/m2 on day
2, and 500 mg/m2 on day 3.15,43,45
Concomitant administration of dimethyl sulfoxide
(DMSO) is not recommended,15,43,46 as this has been associated with an increased occurrence of wounds.43
DMSO

DMSO is a topical organosulfur solvent that increases
skin permeability and, therefore, augments absorption
and subsequent dispersion of the extravasated agent,11,30,47
and functioning as a free-radical scavenger.11 Ninety-nine
percentage of DMSO is applied topically and may improve
outcomes for smaller anthracycline extravasations. It was
shown to be effective in resolving anthracycline extravasation in a prospective pilot trial of 20 patients. No patient
required surgical intervention or had lesion formation.48
However, there is a lack of evidence using objective fluorescence biopsy data, and thus routine use in anthracycline extravasation remains controversial.47 However,

5

PRS Global Open • 2018
DMSO in conjunction with cold compresses remains the
most common acute therapy minor anthracycline extravasation, particularly if dexrazoxane is not available.11
DMSO should be implemented within the first 10–25
minutes of extravasation,9 while minimizing exposure to
unaffected skin, followed by hydrocortisone if erythema is
present,9 and then a cold compress. This process should
be repeated every 2 hours for the first day, after which the
frequency is reduced.9
Sodium Thiosulfate

Sodium thiosulfate functions as an additional target
for alkylation and can hypothetically neutralize certain
vesicants, specifically mechlorethamine (nitrogen mustard, no longer commercially available) or concentrated
cisplatin.49–51 However, while many providers report the
use of sodium thiosulfate, no randomized clinical trials
have been conducted on its efficacy.51
When administered, sodium thiosulfate is injected subcutaneously in a pinwheel fashion around the affected tissue. Four to 8 mL of 10% sodium thiosulfate is mixed with
6 mL of sterile water.50 Two milliliter of sodium thiosulfate
solution is injected for every milligram of mechlorethamine or 100 milligrams of cisplatin infiltrated.
Gault Method

The Gault Method of saline washout for extravasation
injuries was first described in 1993.26 This method involves
early saline washout with subsequent liposuction via a
small incision. Forty-four of the 96 patients studied underwent early washout. Eighty-six percentage healed with
no soft tissue loss compared with 15% in the late referral
group. In areas with less subcutaneous fat, Gault describes
injection 1 unit of hyaluronidase. This is followed by making 4 small incisions surrounding the extravasated area. Finally, the extravasation area is flushed with normal saline,
resulting in irrigation of subcutaneous tissue and efflux
through the previously placed incisions.26
Dressings

In the event of tissue necrosis, the wound should be
dressed in a manner to promote a moist, clean, and warm
environment, while removing excess exudate.52,53 Eschar
and necrotic tissue can impair reepithelialization and
strong consideration should be given to debridement
once the extent of tissue death has demarcated.54 Plain
gauze (wet to dry dressings), while beneficial in debriding the wound bed on removal, can also traumatize viable
healthy tissue, be painful, and needs frequent dressing
changes to be effective. Nonadherent dressings [ie, Xeroform (Tyco Healthcare/Kendall, Mansfield, Mass.) and
Adaptic [Johnson and Johnson, Somerville, N.J.)] can
maintain a moist environment in epithelializing wounds
and reduce pain with dressing changes, however should
be changed daily to prevent them from drying and traumatizing the tissue bed on removal. Hydrocolloid dressings [DuoDERM (Convatec, Bridgewater, N.J.), Exuderm
(Medline, Havre de Grace, MD), Comfeel (Coloplast,
Minneapolis, Minn.), etc] can absorb mild amounts of exudate, maintain a moist environment, and minimize skin
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trauma with dressing changes. They have been shown to
be of benefit in the neonatal population.55 Wounds with
higher degrees of exudate may require more absorptive
dressings such as alginates or hydrofibers.
Surgical Management

In the majority of instances, conservative management is successful, as only 1 in 3 vesicants results in ulceration.56 Surgical management may become indicated
if soft-tissue necrosis develops. Healing capability is typically impaired due to a lack of granulation tissue and
restricted epithelial ingrowth resulting in ulcer progression.56 In patients undergoing chemotherapeutic treatment, open wounds may present an increased infection
risk and delays in treatment. A discussion between medical oncologists and the surgical team is critical to determine the optimal treatment course and timeframe for
the patient.
Debridement (with or without reconstruction) is indicated if extravasation results in continuous pain (persisting for 1–2 weeks), persistent ulceration, or full-thickness
skin necrosis.9,11,14,15,46,57 Fasciotomy is the treatment of
choice if compartment syndrome develops.6,41

CONCLUSIONS

Iatrogenic injuries secondary to intravenous extravasation are commonplace in hospitals. In severe cases,
limb loss is a potential consequence of poor or delayed
management. Nursing algorithms for management of
extravasation injuries are usually directed toward consultation of a wound care team immediately after identification, who may implement local interventions in the
appropriate time-sensitive manner. Hospitals without a
dedicated wound care team trained in these interventions will often default to plastic surgical consultation,
making an understanding of available interventions
essential to the initial evaluation and management of
these injuries. Guidelines for the treatment of extravasation injuries facilitate decision making, given their
time-sensitive nature. Appropriate immediate management may reduce further damage, limb loss, and even
avoid potential litigation. Although there is no standardized protocol for extravasations injuries, a proposed treatment algorithm is shown in Supplemental
Digital Content 1.
The goal of this article was to provide plastic surgeons and trainees with a comprehensive overview of the
acute management of intravenous extravasation injuries.
Our hope is that this will serve as an effective resource
for caregivers treating acute extravasation injuries (See
figure, Supplemental Digital Content 1, which displays
the treatment algorithm, http://links.lww.com/PRSGO/
A724). Though the decision for surgical versus nonsurgical management is often a clear one for plastic surgeons,
local interventions, and therapies are often indicated and
under-utilized in the immediate postextravasation period.
Thorough knowledge of these interventions should be a
basic requirement in the armamentarium of plastic surgery consultants.
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